ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Analyst Ratings
USA - NASDAQ:ZNTL - US98943L1070 - Common Stock
1.5 USD
+0.01 (+1.01%)
1.47 USD
-0.03 (-2%)
ChartMill assigns a Buy % Consensus number of 77% to ZNTL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 6.31. This target is 320.75% above the current price.
ZNTL was analyzed by 15 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about ZNTL.
In the previous month the buy percentage consensus was at a similar level.
ZNTL was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-07 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-15 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-28 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-03-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-30 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-01-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-28 | UBS | Maintains | Neutral -> Neutral |
| 2024-11-15 | Guggenheim | Maintains | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-16 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-08-12 | Wedbush | Upgrade | Underperform -> Neutral |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-20 | UBS | Downgrade | Buy -> Neutral |
| 2024-06-18 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-06-18 | Stifel | Maintains | Buy -> Buy |
| 2024-06-18 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-06-18 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2024-06-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-08 | Stifel | Maintains | Buy -> Buy |
| 2024-05-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-28 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-02-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-08 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-11-07 | Stifel | Maintains | Buy -> Buy |
| 2023-11-07 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-11-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-10 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-08-10 | Wells Fargo | Maintains | Overweight -> Overweight |
ZENTALIS PHARMACEUTICALS INC / ZNTL FAQ
What is the average price target for ZENTALIS PHARMACEUTICALS INC (ZNTL) stock?
15 analysts have analysed ZNTL and the average price target is 6.31 USD. This implies a price increase of 320.75% is expected in the next year compared to the current price of 1.5.
How do analysts rate ZENTALIS PHARMACEUTICALS INC (ZNTL)?
The consensus rating for ZENTALIS PHARMACEUTICALS INC (ZNTL) is 77.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for ZENTALIS PHARMACEUTICALS INC stock?
The number of analysts covering ZENTALIS PHARMACEUTICALS INC (ZNTL) is 15.